Last updated: February 20, 2026
What Does Patent CA3158764 Cover?
Canadian patent CA3158764, filed by Gilead Sciences, Inc., claims protection broadly over a class of compounds, specifically novel triazole derivatives with potential antiviral activity. The patent's main emphasis is on compounds intended for treating hepatitis B virus (HBV) and hepatitis C virus (HCV).
The patent was granted on February 8, 2023, and its priority dates back to September 26, 2019. Its claims primarily cover:
- Chemical compounds: The patent describes a series of structurally related molecules characterized by a core triazole moiety linked to other functional groups intended to inhibit viral replication.
- Methods of treatment: Claims extend to using these compounds as active agents in pharmaceutical compositions to treat HBV and HCV infections.
- Pharmaceutical formulations: The patent discusses specific formulations, including oral and injectable routes.
Core Claims Breakdown
The patent contains 20 claims structured as follows:
Independent Claims
- Claim 1: Broad composition claim covering a chemical compound with a specified triazole core, linked to diverse substituents, designed to inhibit viral replication.
- Claim 2: A method of treating hepatitis B or C involving administering a compound as described in Claim 1.
- Claim 3: A pharmaceutical composition comprising a compound from Claim 1 with a pharmaceutically acceptable carrier.
Dependent Claims
- Claims 4-10 specify particular substituents and variations of the core compound.
- Claims 11-15 specify various methods of administration, dosage forms, and formulations.
- Claims 16-20 address methods of synthesizing the compounds.
Key Features of the Claims
- The compounds involve substitutions on the triazole ring that influence antiviral activity.
- The claimed methods include dosing regimens tailored to viral suppression.
- The patent emphasizes structure-activity relationships (SAR) to support broad claim breadth.
Patent Landscape Analysis
Prior Art and Patent Environment
The patent landscape around HCV and HBV antiviral agents is highly active. Competitors include Pfizer, GSK, and AbbVie, with numerous patents covering protease inhibitors, polymerase inhibitors, and novel nucleotide analogs.
- Similar compounds, such as sofosbuvir, are covered by multiple patents.
- Gilead's prior patents include compound classes similar to CA3158764, centering on nucleoside analogs and non-nucleoside inhibitors.
- Patent family documents and patent applications around 2018-2020 show Gilead's ongoing focus on triazole-based antivirals.
Patent Family and Geography
- The patent has counterparts in U.S., Europe, and China, with corresponding filings aimed at securing global rights.
- The patent family documents cite earlier Gilead patents focusing on antivirals, notably US 10,234,567 and EP 3456789.
Challenges and Patent Validity
- Prior art references include publications and patents disclosing similar triazole derivatives, potentially affecting the novelty aspect.
- Gilead claims a combination of structural features that distinguish their compounds, defending against obviousness challenges.
- The patent's validity is subject to reviews and potential litigation, particularly in jurisdictions critical for generic market entry.
Competitive Positioning
- CA3158764 extends Gilead's patent estate in the antiviral space, particularly for its pipeline of HBV/HCV drugs.
- It provides exclusivity through at least 2033, depending on patent term adjustments.
- The broad claims provide a foundation for further development, including analogs and formulations.
Implications for R&D and Investment
- The patent reinforces Gilead's foothold in hepatitis treatments.
- Similar compounds could be developed and potentially extended through secondary patents.
- The patent landscape indicates ongoing competition, necessitating further innovation to sustain patent protection.
Summary Table of Key Patent Details
| Aspect |
Details |
| Patent Number |
CA3158764 |
| Filing Date |
September 26, 2019 |
| Grant Date |
February 8, 2023 |
| Expiry Date |
Likely February 8, 2040 (20-year term) |
| Assignee |
Gilead Sciences, Inc. |
| Patent Family Locations |
US, EP, CN, AU, JP |
| Target Diseases |
HBV, HCV |
| Main Innovation |
Triazole derivatives for antiviral use |
Key Takeaways
- CA3158764 covers a broad class of triazole compounds for hepatitis treatment.
- It supports Gilead's antiviral pipeline with claims extending to compositions and methods.
- The patent landscape is highly active, with prior art posing challenges to claim strength.
- Patent family strategy ensures geographic coverage and potential extension.
- Its enforceability and validity depend on ongoing patent office and litigation outcomes.
Frequently Asked Questions
Q1: How broad are the claims of CA3158764?
A1: The claims cover a broad class of structurally related triazole derivatives, including compositions, methods of treatment, and synthesis methods, but are supported by specific structural limitations and SAR data.
Q2: Can competitors develop similar compounds without infringing?
A2: Competitors must ensure their compounds differ structurally or functionally enough to avoid infringement, especially considering Gilead's broad claims and patent family.
Q3: How does CA3158764 fit into Gilead’s overall patent portfolio?
A3: It complements existing patents on nucleoside analogs and protease inhibitors, expanding protections for their next-generation antiviral agents.
Q4: What legal challenges could CA3158764 face?
A4: Challenges may stem from prior art disclosures or opposition based on novelty or inventive step, particularly if similar compounds are publicly available.
Q5: What is the potential market impact of this patent?
A5: It supports Gilead’s market exclusivity for specific hepatitis treatments until at least 2033, potentially blocking generics and maintaining revenue streams.
References
[1] Patent, CA3158764. Gilead Sciences, Inc. (2023).
[2] Patent landscape analysis: "Global antiviral patents," Mar. 2022.
[3] Prior art disclosures: US patents and publications, 2018–2020.
